Answers are grounded in this paper and cite their sources.
Donor-derived cell-free DNA (dd-cfDNA) is a promising noninvasive biomarker for detecting acute rejection in kidney transplant recipients, but its prognostic value in patients with stable graft function remains unclear. This study evaluated the association between dd-cfDNA levels and long-term clinical outcomes. We retrospectively analyzed 267 kidney transplant recipients with stable renal function between January 2020 and July 2023, stratified by plasma dd-cfDNA levels into three groups: A (<1%, n = 205), B (1–<2%, n = 34), and C (≥2%, n = 28). Each patient contributed a single index dd-cfDNA measurement obtained during routine outpatient follow-up, which defined baseline; the interval from transplantation to the index measurement did not differ among groups (p = 0.124). Clinical outcomes included changes in serum creatinine, incidence of adverse events, graft loss, patient mortality, and biopsy findings over three years. Creatinine levels remained stable in Group A but increased significantly in Groups B and C from baseline to year 3 (1.38 to 1.96 mg/dL, p < 0.0001; and 1.36 to 1.84 mg/dL, p = 0.0019, respectively). Adverse events were significantly more frequent in Groups B (41.2%) and C (42.9%) compared with Group A (9.8%, p < 0.001). Graft loss rates were 0.98%, 11.76%, and 7.14% in Groups A, B, and C, respectively (p = 0.002), and mortality showed a significant increasing trend across groups (p = 0.023). Elevated dd-cfDNA levels are associated with adverse long-term outcomes in kidney transplant recipients with stable graft function, suggesting that dd-cfDNA may serve as a valuable tool for early risk stratification and long-term monitoring in transplant care.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: